KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Moderna (MRNA) Revenue (2017 - 2026)

Moderna (MRNA) has disclosed Revenue for 10 consecutive years, with $389.0 million as the latest value for Q1 2026.

  • For Q1 2026, Revenue rose 260.19% year-over-year to $389.0 million; the TTM value through Mar 2026 reached $2.2 billion, down 28.5%, while the annual FY2025 figure was $1.9 billion, 39.93% down from the prior year.
  • Revenue hit $389.0 million in Q1 2026 for Moderna, down from $678.0 million in the prior quarter.
  • Across five years, Revenue topped out at $6.1 billion in Q1 2022 and bottomed at $108.0 million in Q1 2025.
  • Average Revenue over 5 years is $1.9 billion, with a median of $1.0 billion recorded in 2025.
  • Year-over-year, Revenue plummeted 92.76% in 2023 and then skyrocketed 260.19% in 2026.
  • Moderna's Revenue stood at $5.1 billion in 2022, then crashed by 44.71% to $2.8 billion in 2023, then crashed by 65.64% to $966.0 million in 2024, then decreased by 29.81% to $678.0 million in 2025, then tumbled by 42.63% to $389.0 million in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $389.0 million, $678.0 million, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.